Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBSErve-LN: Real-world belimumab use in lupus nephritis
ChiCTR2500102427Phase 4Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belimumab in lupus nephritis (LN), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Maintaining renal function at 24 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
belimumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR2500102427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102427.